Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 15, 2021 17:54 ET | Source: Anchiano Therapeutics

Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing

Anchiano shareholders approve all resolutions at shareholder meeting The merged company is expected to receive approximate gross proceeds from the private financing of $45.5 million, which will be...
December 15, 2020 09:00 ET | Source: Anchiano Therapeutics

Anchiano Therapeutics and Chemomab Announce Entry Into Definitive Merger Agreement

Merger brings lead compound CM-101, a first in class anti-CCL24 antibody into advanced clinical development for fibrosis-related diseases with significant unmet medical need Concurrent PIPE...
May 26, 2020 08:00 ET | Source: Anchiano Therapeutics

Anchiano Appoints Stan Polovets as Chairman of the Board

CAMBRIDGE, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) today announced that Mr. Stan Polovets has been elected chairman of its board of...
May 11, 2020 16:01 ET | Source: Anchiano Therapeutics

Anchiano Therapeutics Reports First Quarter 2020 Financial Results

CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a preclinical biopharmaceutical company dedicated to the discovery and development of new...
May 05, 2020 18:13 ET | Source: Anchiano Therapeutics

Anchiano Appoints Steve DiPalma as Chief Financial Officer

CAMBRIDGE, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) today announced it has appointed Mr. Steve DiPalma as its Chief Financial Officer. Mr....
April 17, 2020 16:01 ET | Source: Anchiano Therapeutics

Anchiano to Hold Virtual Annual Meeting of Shareholders

CAMBRIDGE, Mass., April 17, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) today announced it has elected to hold its 2020 Annual General Meeting of Shareholders...
March 18, 2020 08:00 ET | Source: Anchiano Therapeutics

Anchiano Therapeutics Reports Year-End 2019 Financial Results

CAMBRIDGE, Mass., March 18, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a biopharmaceutical company focused on discovery and development of novel therapies to...
January 17, 2020 16:05 ET | Source: Anchiano Therapeutics

Anchiano Therapeutics Announces Record Date for 2020 Annual General Meeting of Shareholders

CAMBRIDGE, Mass., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) announced today that its board of directors approved the record date for the Company’s...
November 15, 2019 08:30 ET | Source: Anchiano Therapeutics

Anchiano Discontinues Phase 2 Codex Study Evaluating Inodiftagene Vixteplasmid in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC); Company Focuses on Advancing Pan-RAS Inhibitor Program

CAMBRIDGE, Mass., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano” or the “Company”), a biopharmaceutical company focused on discovery and development of...
November 15, 2019 08:30 ET | Source: Anchiano Therapeutics

Anchiano Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a biopharmaceutical company focused on discovery and development of novel therapies to...